结果:A、B和C组的无进展生存(progression-free survival,PFS)时间分别为4.5、6.1和5.6个月(P=0.50),总生存(overall survival,OS...
基于4个网页-相关网页
的无进展生存期 Time to progression ; progression-free survival ; PFS ; TTP
的无进展生存率 progress free survival ; PFS
组的无进展生存 progression-free survival ; PFS
的无进展生存时间 Time to progression ; TTP
患者的无进展生存期 progression-free survival ; PFS
两组的无进展生存期 progression-free survival ; PFS
者的无进展生存 TTP ; time to progression
的总体无进展生存时间 progression-free survival ; PFS
的中位无进展生存期 progression free surwival
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
多数的专家认为这得益于“无进展生存”,阿瓦斯丁已经被许多肿瘤学家作为“未贴签”药物用于治疗,足以完全通过审批。
Most scientific experts consider this benefit "progression-free survival," sufficient for full approval, and many oncologists have been using Avastin as an "off-label" drug for this purpose.
他指出,研究结果还表明,患者的一个子集可能表现出更显著的效应。这在无进展生存期(PFS)的结果中能明显地看出来。
The findings also suggest that a subset of patients may be achieving a more significant benefit. This is apparent in the results of PFS, he pointed out.
应用推荐